Navigation Links
Accera, Inc. to Support the Alzheimer's Foundation of America's National Memory Screening Day Through On-line Awareness Effort
Date:8/11/2009

BROOMFIELD, Colo., Aug. 11 /PRNewswire/ -- Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system diseases, announced today the launch of its "Lost & Found" campaign, an on-line initiative whereby each visit to www.lostandfoundcampaign.com prompts a $1 donation by Accera to support the Alzheimer's Foundation of America (AFA).

Every AD patient, caregiver or family who visits the "Lost & Found" Web site may participate in this fundraising campaign by simply selecting an icon that represents something they have lost or forgotten that day. Clicking on an icon will trigger a donation from Accera to AFA at no cost to the individual participants. All funds generated throughout this initiative will be donated to AFA on November 17, 2009, "National Memory Screening Day," to further AFA's efforts to support individuals with Alzheimer's disease and their families. The Web site also contains information on current treatment therapies and educational links for patients and caregivers.

National Memory Screening Day, an annual initiative sponsored by AFA, provides free, confidential memory screenings to individuals concerned about memory loss with the objective of early detection and intervention. Qualified healthcare professionals offer the face-to-face screenings at convenient locations in communities across the nation.

"We are pleased to be the recipients of Accera's 'Lost & Found' campaign as we work to raise awareness about National Memory Screening Day," said Eric J. Hall, AFA's president and chief executive officer. "With the incidence of Alzheimer's disease escalating, AFA is extremely appreciative of those who understand the vital need for support services and the difference they can make for individuals with dementia and their families."

Steve Orndorff, Ph.D., President and CEO of Accera, Inc., stated, "Our goal through this effort is to signal to patients and caregivers that there are many people and companies, like Accera, dedicated to combating this devastating disease." He continued, "With the downturn of the economy, we wanted to enable individuals to make a contribution towards this effort without having to donate their own income. Through our initiative we hope to improve the quality of life for patients and caregivers."

"Lost & Found" submissions will be accepted on-line through November 13,

2009.

About Axona(TM)

Axona is a first-in-class medical food for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease. Dispensed by prescription, Axona targets the metabolic deficiencies and imbalances associated with Alzheimer's disease by providing an alternative energy source for brain cells. With simple administration and once-a-day convenience, Axona is complementary to current Alzheimer's disease therapies. For more information about Axona, please visit www.about-axona.com or ask your physician.

About the Alzheimer's Foundation of America (AFA)

The Alzheimer's Foundation of America (AFA) is a nonprofit organization based in New York City that focuses on providing optimal care to individuals with Alzheimer's disease and related illnesses, and their families, and unites more than 1,200 member organizations nationwide that provide hands-on programs and services to meet the educational, social, emotional and practical needs of those affected by the disease. AFA's services include a toll-free hot line with counseling by licensed social workers, a free caregiver magazine, professional training and its signature annual National Memory Screening Day. For information, call 866-AFA-8484 or visit www.alzfdn.org.

About Alzheimer's Disease

Alzheimer's disease, the most common form of dementia, is a progressive and fatal disease. In the United States, 5.2 million people are living with AD, and it has become the seventh leading cause of death. The disease attacks brain cells, resulting in loss of memory, executive function and language skills.

AD significantly impacts millions of family members and other caregivers - mentally, physically and financially. The National Family Caregiver Alliance estimates that approximately 80 percent of caregivers provide unpaid assistance seven days a week. With the lack of innovative new medications for AD, both patients and caregivers are seeking alternatives to improve quality of life.

About Accera, Inc.

Accera, Inc. is a privately held commercial-stage biotechnology company that developed and now markets Axona in the US. Axona is a prescription-only medical food intended for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease. In clinical trials, Axona has been shown to safely improve cognitive function and memory in AD patients. Axona addresses the hypometabolism or defective metabolism of glucose that occurs in those areas of the brain that are involved in Alzheimer's disease. Accera engages in research, development and commercialization of other clinical applications for Axona. For more information about Accera, please visit www.accerapharma.com.

    Contacts:
    Accera, Inc.
    Steve Orndorff, Ph.D. President and CEO sorndorff@accerapharma.com

    Richard Lewis Communications, Inc.
    (212) 827-0020
    Andrew Mielach amielach@rlcinc.com
    Tamara Bright tbright@rlcinc.com


'/>"/>
SOURCE Accera, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Accera, Inc. Launches Neuera Pharmaceuticals, Inc.
2. Accera, Inc. to Present at Upcoming Investor Conferences
3. Dr. Thomas Werner Elected to Accera, Inc.s Board of Directors
4. Accera, Inc. Sponsors Alzheimers Associations 2009 ICAD Conference
5. Accera, Inc. Completes $35 Million Series C Financing
6. Accera, Inc. Names William T. Poncy Vice President of Commercial Development
7. Accera, Inc. to Present at the 4th Annual BIO Investor Forum
8. Zeus Expands International Support With New Hires
9. GenVec Expands Contract Supporting Malaria Vaccine Program
10. Biomodels Expands Efforts in Cancer Supportive Care, Pulmonary Fibrosis; Preclinical Research Organization Names Dr. Stephen T. Sonis as Partner
11. NIH funds support UAB joint replacement research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry ... Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s mission ... hardware projects are designed, built and brought to market. , The Design Lab ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... Pleasant Prairie, WI (PRWEB) , ... June 23, ... ... sciences consultancy focused on quality, regulatory and technical consulting, provides a free ... webinar is presented on July 13, 2016 at 12pm CT at no charge. ...
(Date:6/22/2016)... 22, 2016 Cell Applications, Inc. and ... to produce up to one billion human induced ... one week. These high-quality, consistent stem cells enable ... and spend more time doing meaningful, relevant research. ... high-volume manufacturing process that produces affordable, reliable HiPSC ...
Breaking Biology Technology:
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):